[go: up one dir, main page]

WO2007000967A1 - Médicament contre l'infarctus cérébral - Google Patents

Médicament contre l'infarctus cérébral Download PDF

Info

Publication number
WO2007000967A1
WO2007000967A1 PCT/JP2006/312708 JP2006312708W WO2007000967A1 WO 2007000967 A1 WO2007000967 A1 WO 2007000967A1 JP 2006312708 W JP2006312708 W JP 2006312708W WO 2007000967 A1 WO2007000967 A1 WO 2007000967A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
glycyrrhizin
cerebral infarction
therapeutic agent
infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/312708
Other languages
English (en)
Japanese (ja)
Inventor
Yasunobu Antoku
Fumihiko Koike
Ryo Tanaka
Katsuhiro Ishibashi
Takashi Naito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minophagen Pharmaceutical Co Ltd
Original Assignee
Minophagen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minophagen Pharmaceutical Co Ltd filed Critical Minophagen Pharmaceutical Co Ltd
Publication of WO2007000967A1 publication Critical patent/WO2007000967A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals

Definitions

  • the anticoagulant heparin the antiplatelet drug ozadarel sodium, the antithrombotic drug argatroban, the brain protective drug edaravone, etc. can be mentioned as conventional cerebral infarction drugs.
  • the first invention of the present invention is glycyrrhizin and Z or a pharmaceutically acceptable product thereof. It is a therapeutic agent for cerebral infarction containing a salt as an active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention décrit un médicament contre l'infarctus cérébral qui contient de la glycyrrhizine et/ou un sel de qualité pharmaceutique de cette substance au titre de principe actif. Il peut être employé, au titre de sel de qualité pharmaceutique, un sel d'ammonium de glycyrrhizine, un sel de métal alcalin tel que le glycyrrhizinate de sodium ou de potassium, le sel de choline de la glycyrrhizine, etc. Il est également possible d'employer un sel de calcium, de magnésium, d'aluminium, etc.
PCT/JP2006/312708 2005-06-28 2006-06-26 Médicament contre l'infarctus cérébral Ceased WO2007000967A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005188876 2005-06-28
JP2005-188876 2005-06-28

Publications (1)

Publication Number Publication Date
WO2007000967A1 true WO2007000967A1 (fr) 2007-01-04

Family

ID=37595218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/312708 Ceased WO2007000967A1 (fr) 2005-06-28 2006-06-26 Médicament contre l'infarctus cérébral

Country Status (2)

Country Link
TW (1) TW200744616A (fr)
WO (1) WO2007000967A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692086A (zh) * 2016-12-12 2017-05-24 乐普药业股份有限公司 一种复方甘草酸苷片剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS STN; 1994, EGASHIRA T. ET AL.: "Effects of glycyrrhizin on lipid peroxidation in rat brain following transient middle cerebral artery occlusion", XP003006051 *
DATABASE CAPLUS STN; CAI H. ET AL.: "Effects of glycyrrhizic acid on mitochondria adenosine triphosphatase (ATPase) in canine cerebral tissue after reperfusion", XP003006052 *
ITO M. ET AL.: "Medical Dictionary", 1 March 2003, IGAKU-SHOIN LTD, article "Nokosoku", pages: 1907, XP003006050 *
YAKURI TO CHIRYO, vol. 22, no. 7, 1994, pages 2981 - 2989 *
ZHONGGUO YAOLIXUE TONGBAO, vol. 12, no. 6, 1996, pages 549 - 551 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692086A (zh) * 2016-12-12 2017-05-24 乐普药业股份有限公司 一种复方甘草酸苷片剂及其制备方法

Also Published As

Publication number Publication date
TW200744616A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
Craig Phenytoin poisoning
WO2012060719A1 (fr) Composition combinée
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
CN116761593A (zh) 和厚朴酚在制备用于治疗脑膜瘤的药物中的用途
JP2015522077A5 (fr)
KR20180014834A (ko) 카보플라틴을 함유하는 조성물 및 용도
JP5161472B2 (ja) 鎮痛用組成物
TWI760306B (zh) 供治療癌症之口服投予紫杉醇及Ｐ-ｇｐ抑制劑的治療性組合
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
CN113289023B (zh) 一种阿利沙坦酯或其盐与利尿剂的药物组合物
JPH03170475A (ja) 抑うつ症治療剤
JP3415643B2 (ja) 筋ジストロフィー症治療薬
JP6454436B1 (ja) ペマフィブラートを含有する医薬
WO2007000967A1 (fr) Médicament contre l'infarctus cérébral
Porter et al. Iron chelation
TWI631944B (zh) 氯硝柳胺及其衍生物的用途
Koshy et al. Thiopentone–midazolam mixture as an induction agent for general anasthesia on ‘in-patients’
JP6042886B2 (ja) 早漏症治療用の薬学組成物
CN110891574B (zh) 用于预防和/或治疗肝细胞癌的美格列明
US20120328717A1 (en) Pharmaceutical kit for treating neuronal damages
Mimi et al. Tuberculosis and chronic renal failure; therapy patterns
RU2483715C2 (ru) Твердая лекарственная форма препаратов мемантина и его солей
Shannon Theophylline: Its rise, demise, and resurrection
WO2024128311A1 (fr) Composition pharmaceutique pour malformations vasculaires et procédé pour soigner des malformations vasculaires
Wu et al. Case Report Anesthetic management of diabetic foot amputation in a patient with renal failure and maintenance hemodialysis: case report and short communication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOST OF RIGHTS PURSUANT TO RULE 112(1)EPC, FORM 1205A DATED 22.04.08

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 06767325

Country of ref document: EP

Kind code of ref document: A1